Bisphosphonate: A novel treatment for pigmented villonodular synovitis

Annals of Surgical Oncology

Volumn 15, Issue 8, 2008, Pages 2350-2351

  Namazi, Hamid ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; HEMOSIDERIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; RAC PROTEIN; RAS PROTEIN; RHO FACTOR;

BONE DESTRUCTION; BONE MINERAL; CELL INFILTRATION; CELL PROLIFERATION; DRUG MECHANISM; GIANT CELL; GIANT CELL TUMOR; HIP; HUMAN; JOINT CAVITY; KNEE; LETTER; MACROPHAGE; MONONUCLEAR CELL; OSTEOCLAST; OSTEOLYSIS; PIGMENTED VILLONODULAR SYNOVITIS; SYNOVIAL BURSA; SYNOVIOCYTE; TEMPOROMANDIBULAR JOINT; TUMOR RECURRENCE;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; SYNOVITIS, PIGMENTED VILLONODULAR; TREATMENT OUTCOME;

EID: 48149110125     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9797-6     Document Type: Letter

References (15)

1. RC Martin DL Osborne MJ Edwards 2000 Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence Oncol Rep 7 413 9
2. W Leutheuser G Moll A Schulz 1983 Localised (circumscribed) nodular synovitis Arch Orthop Trauma Surg 102 19 22
3. MA Rosa M Galli G Fada 2000 Proliferating cell nuclear antigen labelling index in localised pigmented villo-nodular synovitis and its relationship to the size of nodules Int Orthop 24 197
4. JM Darling SR Golding Y Harada 1997 Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts Am J Pathol 150 1383 93
5. W Yoshida M Uzuki A Kurose 2003 Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis Hum Pathol 34 65 73
6. YS Lau A Sabokbar CL Gibbons 2005 Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue Hum Pathol 36 945 54
7. SD Neale R Kristelly R Gundle 1997 Giant cells in pigmented villo nodular synovitis express an osteoclast phenotype J Clin Pathol 50 605 8
8. Y Hu S Yu 2002 Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor Zhonghua Bing Li Xue Za Zhi 31 128 31
9. GJ Atkins P Kostakis C Vincent 2006 RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone J Bone Miner Res 21 1339 49
10. T Morgan GJ Atkins MK Trivett 2005 Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB Am J Pathol 167 117 28
11. RL Fleurence CP Iglesias JM Johnson 2007 The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature Pharmacoeconomics 25 913 33
12. KL Kavanagn K Guo JE Dunford 2006 The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc Natl Acad Sci 103 7829 34
13. FP Coxan K Thompson MJ Rogers 2006 Recent advances in understanding the mechanism of action of bisphosphonates Curr Opin Pharmacol 6 307 12
14. G Martini L Gennari D Merlotti 2007 Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone Bone 40 457 63
15. H Dobring LC Hofbauer V Viereck 2006 Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients Osteoporos Int 17 693 703